LGD-3303
Shop LGD-3303 on KimeraChems · code GUIDE (10% off)Definition
LGD-3303 is an investigational selective androgen receptor modulator (SARM) studied in laboratory settings for its androgen receptor (AR) activity in skeletal muscle- and bone-focused research models. Unlike traditional anabolic steroids, SARMs are designed to preferentially activate androgen receptor signaling in specific tissues, although observed tissue selectivity varies depending on the experimental model, dose, and duration of exposure. LGD-3303 is not approved for human or veterinary use and is supplied strictly for laboratory and analytical research purposes.
Mechanism of Action
LGD-3303 is studied as a selective androgen receptor agonist. In experimental systems, androgen receptor activation influences transcriptional programs involved in protein synthesis, muscle-cell differentiation, and bone remodeling. Common areas of mechanistic investigation include
- Androgen receptor activation: Studied for its ability to bind the androgen receptor and regulate androgen-responsive gene transcription
- Anabolic signaling: Investigated for activation of pathways associated with lean-tissue accretion and muscle protein synthesis in controlled models
- Bone biology: Explored in studies evaluating bone-remodeling biomarkers, bone mineral density, and skeletal strength
- Tissue selectivity: Assessed by comparing androgen receptor activity across skeletal muscle, bone, prostate, liver, and other androgen-sensitive tissues
- Dose-dependent pharmacology: Investigated for potential tradeoffs between tissue selectivity and off-target physiological effects as exposure increases
Areas of Investigation
LGD-3303 is commonly studied in
- Lean-mass and skeletal-muscle function research
- Bone-density, bone-strength, and bone-turnover studies
- Androgen receptor pharmacology and tissue-selective signaling
- Comparative studies involving other SARMs or androgen receptor agonists
- Recovery, immobilization, and catabolic-stress models in which androgen signaling is an experimental variable
Safety Profile
Reported observations are model- and exposure-dependent and may include
- Suppression-like findings involving endogenous gonadotropin biomarkers in certain in vivo models
- Alterations in lipid biomarkers and hepatic-enzyme measurements depending on compound, exposure level, and study duration
- Changes in blood-pressure-related or hematologic biomarkers in selected experimental paradigms
- Androgenic findings in non-target tissues when tissue selectivity is exceeded
- Rebound changes in endocrine biomarkers following discontinuation in some research models
Interaction Notes
LGD-3303 is often explored alongside interventions that overlap with androgenic and anabolic signaling.
For educational purposes only. Not for human consumption.